Nael Ismail: Gene and Cell Therapy Are Transforming the Treatment of Human Genetic Diseases
Nael Ismail, Clinical Advisor at Vgenomics, shared a post on Linkedin about a recent article by Busra Cetin et al. published in Journal of Cellular and Molecular Medicine, adding:
“Genetic diagnosis should not be the end of the story.
For decades, medical genetics has focused heavily on identifying the variant, establishing the diagnosis, and explaining the disease.
But what happens next?
The therapeutic landscape is changing rapidly.
Gene therapy, cell therapy and CRISPR-based genome editing are moving genetic medicine from describing disease to potentially modifying its molecular cause.
We are already seeing this transition in real patients: spinal muscular atrophy, inherited retinal disease, hemophilia, B-thalassemia, sickle cell disease and cancers are among the areas where advanced genetic and cellular therapies have reached clinical practice.
And yet, our healthcare systems often remain structured around an older model:
Diagnose, then report, refer, and manage symptoms.
That model is increasingly inadequate for some genetic diseases.
The real challenge is no longer simply whether we can identify the molecular abnormality.
It is whether we can translate that molecular knowledge into meaningful clinical action.
Of course, gene and cell therapies come with enormous challenges: delivery, immune responses, off-target effects, durability, manufacturing, long-term safety, regulation and cost.
But these challenges should push us toward better clinical integration, not toward treating genomics as an endpoint.
The future of medical genetics cannot be limited to finding variants.
It must increasingly connect genomic information to molecular mechanisms, therapeutic targets, clinical decisions, and patient outcomes.
That is where medical genetics, clinical genomics, molecular medicine and precision medicine truly converge.
The question is no longer only: ‘What genetic disease does this patient have?’
It is increasingly:
‘Now that we know the molecular cause, what can we actually do about it?'”
Title: Gene and cell therapy of human genetic diseases: Recent advances and future directions
Authors: Busra Cetin, Fulya Erendor, Yunus E Eksi, Ahter D Sanlioglu, Salih Sanlioglu
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause